Innovative Drug Offers Relief for Menopausal Women in England
Veoza, a groundbreaking hot flush prevention drug, will soon be available on the NHS, providing an alternative for women who cannot use hormone replacement therapy.
In a significant move for women's health, the National Institute for Health and Care Excellence (NICE) has approved the use of Veoza, also known as fezolinetant, for women in England who are experiencing distressing hot flushes during menopause. This new drug, which will be available on the NHS, offers a much-needed alternative for the over 500,000 women in England who are unable to use hormone replacement therapy (HRT).
Addressing an Unmet Need
Hot flushes are a common and often debilitating symptom of menopause, affecting the quality of life for many women. For those who cannot or choose not to use HRT, the approval of Veoza provides a new treatment option that can help alleviate this distressing experience. The drug, which works by regulating the body's temperature control mechanisms, has been shown to effectively reduce the frequency and severity of hot flushes in clinical trials.
Source: The Guardian
